Key points are not available for this paper at this time.
Abstract Background: Tirzepatide has been studied for individuals with obesity without diabetesin randomized controlled trials (RCTs). Objectives: The summarize the efficacy and safety of tirzepatide to guide clinical practice. Methods: Databases were searched to identify RCTs that compared tirzepatide with any treatments in this population. Meta-analyses were conducted to compare tirzepatide versus placebo. Standard mean difference (SMD) or risk ratio (RR) with 95% confidence intervals (CIs) were used as appropriate. Results: Three RCTs with 3901 participants were included. Tirzepatide caused weight loss of 18.73% (95% CI: -21.31 to -16.15) versus placebo. The percentages of patients achieving weight loss of 5%, 10%, 15%, and 20% were 92.7%, 84.4%, 73.6%, and 56.1%, respectively. Tirzepatide had greater weight loss than placebo (SMD: -1.61, 95% CI -2.20 to -1.02). It also had a higher likelihood of achieving weight loss ≥ 5%, 10%, 15%, 20%, and 25% compared to placebo. However, tirzepatide had significantly increase in adverse events than placebo (RR: 1.53, 95% CI: 1.18 to 1.98). Conclusions: Tirzepatide can significantly reduce body weight in overweight or obese individuals without diabetes. This weight loss effect might be better than semaglutide and liraglutide. Nonetheless, the increased adverse events warrant careful monitoring.
Liu et al. (2024) studied this question.